Cytotoxic Effects Of Selective Inhibitor Aurora Kinase B On Viability And Metabolic Features Of Human Promyelocytic Leukemia Cell Line
Author(s):
Abstract:
Background And Aim
A goal of modern cancer research is to reach targeted therapies with drugs having fewer side effects. AZD1152 is a highly specific inhibitor of Aurora Kinase B، which leads to the programmed cell death by different mechanisms. The aim of this study was to evaluate the effects of AZD1152 on viability and metabolic activity of NB4 cells (APL derived cell line). Materials And Methods
The cells were treated with various concentrations of AZD1152. After 24، 48 and 72h treatments، the metabolic activity and viability of inhibitor-treated NB4 cells were assessed using MTT and trypan blue dye exclusion assays، respectively. Data were analyzed by applying student’s t-test (Microsoft Excel). Results
A t 25، 50 and 100 nM، AZD1152 reduced the metabolic activity by 9. 2، 15. 5 and 56. 2% (after 24h)، 10. 3، 19. 5 and 59. 9% (after 48h)، and 17. 1، 28. 4 and 64. 8% (after 72h)، respectively. Meanwhile، the percentage of viability was decreased to about 51، 45 and 40% (after 24h)، 39، 36 and 30% (after 48h)، and 34، 32 and 28% (after 72h)، respectively. Conclusion
According to the results، AZD1152 has substantial efficacy on APL cell line and may be applied in some cases، e. g.، for patients who have relapse or who become refractory to the conventional chemotherapy. Further studies are needed to show the molecular mechanisms regulating effects of this anti-cancer agent.Keywords:
Language:
Persian
Published:
Journal of Payavard Salamat, Volume:7 Issue: 3, 2013
Pages:
197 to 206
magiran.com/p1156330
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یکساله به مبلغ 1,390,000ريال میتوانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.
In order to view content subscription is required
Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!